Overview Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112 Status: Completed Trial end date: 2020-07-16 Target enrollment: Participant gender: Summary A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112 Phase: Phase 1 Details Lead Sponsor: Addpharma Inc.